Cite

HARVARD Citation

    Seufferlein, T. et al. (n.d.). 474PA novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial. Annals of oncology. p. . [Online]. 
  
Back to record